NCT00184587

Prophylactic Treatment of Episodic Cluster Headache

Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Norwegian University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache

Detailed description

Cluster headache is an unilateral headache with periodic attacks, that usually lasts for 6 to 12 weeks. The pain is usually unbearable. The attacks are treated with injections of sumatriptan (migraine medication)and inhalation of oxygen. The most common prophylactics today has limited effect and a risk of side effects. Candesartan has in one study shown a clinically significant effect in migraine prophylaxis. The angiotensin II receptor blocker, candesartan is well tolerated with side-effects not significantly different from placebo and with few drug interactions. We therefore wish to investigate the prophylactic effect in treatment of cluster in headache patients. This will be a multicenter, double-blind, randomized, parallel study where the prophylactic effect of candesartan is compared to placebo in a period of 3 weeks. First week 16 mg and the following 2 weeks 32 mg.

Conditions

• Cluster Headache

Interventions

Type	Name	Description
DRUG	candesartan cilexetil
DRUG	placebo

Timeline

• Start date: 2005-03-01
• Primary completion: 2009-06-01
• Completion: 2009-12-01
• First posted: 2005-09-16
• Last updated: 2013-04-23

Locations

1 site across 1 country: Norway